Publications by authors named "Shahneen Sandhu"

96Publications

Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of Lu-PSMA-617 Prior to Prostatectomy.

Eur Urol Focus 2020 Nov 7. Epub 2020 Nov 7.

Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2020.09.021DOI Listing
November 2020

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

N Engl J Med 2020 Sep 20. Epub 2020 Sep 20.

From the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (J.M.), the Spanish National Cancer Research Center, Madrid (D.O.), and Instituto de Investigación Biomédica de Málaga, Málaga (D.O.) - all in Spain; Institut Gustave Roussy, University of Paris Saclay, Villejuif (K.F.), the Department of Medical Oncology, Centre Hospitalier Universitaire Besançon, Besançon (A.T.-V.), and the Department of Medical Oncology, Institut Bergonié, Bordeaux (G.R.) - all in France; Centre Hospitalier de l'Université de Montréal-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal (F.S.), and BC Cancer Agency, Vancouver (K.N.C.) - both in Canada; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S.S.); Tulane University School of Medicine, New Orleans (O.S.); Huntsman Cancer Institute, University of Utah, Salt Lake City (N.A.); John Wayne Cancer Institute, Santa Monica, CA (P.T.); Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey (M.O.); AstraZeneca, Global Medicines Development, Oncology, Gaithersburg, MD (J.K.); Merck, Kenilworth, NJ (J.B.); and Global Medicines Development, Oncology (C.G.), Precision Medicine and Biosamples, R&D Oncology (C.C.), and Translational Medicine (C.A.A.), AstraZeneca, Cambridge, and the Institute of Cancer Research and Royal Marsden, London (J.B.) - both in the United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2022485DOI Listing
September 2020

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.

Future Oncol 2020 Oct 29;16(28):2165-2175. Epub 2020 Jul 29.

Melanoma Institute Australia, The University of Sydney, Royal North Shore & Mater Hospital, St Leonards, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2020-0351DOI Listing
October 2020

Olaparib for Metastatic Castration-Resistant Prostate Cancer.

N Engl J Med 2020 05 28;382(22):2091-2102. Epub 2020 Apr 28.

From the Institute of Cancer Research and Royal Marsden Hospital, London (J. de Bono), and AstraZeneca, Translational Medicine, Cambridge (C.A.A.) - all in the United Kingdom; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (J.M.), the Spanish National Cancer Research Center, Madrid (D.O.), and Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Malaga (D.O.) - all in Spain; Institut Gustave Roussy, University of Paris Sud, Villejuif (K.F.), and the Department of Medical Oncology, Centre Hospitalier Universitaire Besançon, Besançon (A.T.-V.) - all in France; Centre Hospitalier de l'Université de Montréal-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal (F.S.), and BC Cancer Agency, Vancouver (K.N.C.) - all in Canada; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S.S.); Tulane University School of Medicine, New Orleans (O.S.); Huntsman Cancer Institute, University of Utah Comprehensive Cancer Center, Salt Lake City (N.A.); John Wayne Cancer Institute, Santa Monica, CA (P.T.); Radboud University Medical Center, Nijmegen, the Netherlands (N.M.); AstraZeneca, Global Medicines Development, Oncology, Gaithersburg, MD (C.G., J.K., W.W.); Merck, Kenilworth, NJ (J. Burgents); AstraZeneca, Precision Medicine, Oncology Research and Development, Gaithersburg, MD (A.K.); and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1911440DOI Listing
May 2020

Patient-reported outcomes in melanoma survivors at 1, 3 and 5 years post-diagnosis: a population-based cross-sectional study.

Qual Life Res 2020 Aug 5;29(8):2021-2027. Epub 2020 Mar 5.

Australian Cancer Survivorship Centre, a Richard Pratt Legacy, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11136-020-02464-yDOI Listing
August 2020

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617.

Eur J Nucl Med Mol Imaging 2020 Sep 5;47(10):2322-2327. Epub 2020 Mar 5.

Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-020-04723-zDOI Listing
September 2020

E6AP Promotes a Metastatic Phenotype in Prostate Cancer.

iScience 2019 Dec 2;22:1-15. Epub 2019 Nov 2.

Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne 3000, Australia; Department of Clinical Pathology, University of Melbourne, Parkville, VIC 3010, Australia; Department of Biochemistry and Molecular Biology, Monash University, Melbourne 3800, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.isci.2019.10.065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864340PMC
December 2019

F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond.

PET Clin 2020 Jan;15(1):11-22

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia; Department of Medical Oncology, the Peter MacCallum Cancer Centre, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpet.2019.08.007DOI Listing
January 2020

A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies.

Eur J Cancer 2020 01;124:15-24

The Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Grattan Street, Parkville, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.09.009DOI Listing
January 2020

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for Lu-labelled PSMA Radioligand Therapy.

Eur Urol Oncol 2019 11 13;2(6):670-676. Epub 2018 Dec 13.

Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, Melbourne, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.11.007DOI Listing
November 2019

Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.

Prostate 2019 08 18;79(11):1326-1337. Epub 2019 Jun 18.

Department of Anatomy and Developmental Biology, Monash Partners Comprehensive Cancer Consortium, Monash Biomedicine Discovery Institute, Prostate Cancer Research Group, Monash University, Clayton, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23839DOI Listing
August 2019

Microbiome transplantation and modulation of immune related adverse events.

EClinicalMedicine 2019 Feb 12;8:10-11. Epub 2019 Mar 12.

Department of Infectious Diseases and National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eclinm.2019.03.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537550PMC
February 2019

The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors.

J Cancer Surviv 2019 Aug 4;13(4):503-511. Epub 2019 Jun 4.

Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11764-019-00770-0DOI Listing
August 2019

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

N Engl J Med 2019 07 2;381(2):121-131. Epub 2019 Jun 2.

From Monash University (I.D.D., M.F., D.W.P.), Eastern Health (I.D.D.), Australian Urology Associates (M.F.), Monash Health (D.W.P.), and the Peter MacCallum Cancer Centre and the University of Melbourne (S.K.S., S.G.W.), Melbourne, VIC, the National Health and Medical Research Council Clinical Trials Centre, University of Sydney (A.J.M., M.R.S., X.C., W.E.H., E.T., S.Y., A.Y.Z.), the Chris O'Brien Lifehouse (M.R.S., L.G.H., A.Y.Z.), the University of Sydney (L.G.H., G.M.), Royal Prince Alfred Hospital (L.G.H.), Kinghorn Cancer Centre, St. Vincent's Hospital, and Garvan Institute of Medical Research (A.M.J.), Macquarie University (A.Y.Z.), and Western Sydney University (R.R.Z.), Sydney, Concord Cancer Centre, Concord Repatriation General Hospital, Concord, NSW (M.R.S.), Port Macquarie Base Hospital and Mid North Coast Cancer Institute Port Macquarie, Port Macquarie, NSW (S.B.), Sydney Adventist Hospital, Wahroonga, NSW (G.M.), the ANZUP Cancer Trials Group, Camperdown, NSW (M.M.), the Adelaide Cancer Centre and the University of Adelaide (F.P.) and the Royal Adelaide Hospital (T.H.T.), Adelaide, SA, and Orange Health Service, Central West Cancer Care Centre, Orange, NSW (R.R.Z.) - all in Australia; BC Cancer and the University of British Columbia, Vancouver (K.N.C.), the Cross Cancer Institute and the University of Alberta, Edmonton (S.A.N.), Canadian Cancer Trials Group, Queen's University (W.P., F.V.-B.), and the Kingston Health Sciences Center (F.V.-B.), Kingston, ON, and the University of Ottawa and the Ottawa Hospital Research Institute, Ottawa (M.N.R.) - all in Canada; Guy's and St. Thomas' NHS Foundation Trust Biomedical Research Centre, Cancer Research UK and King's College London, and Sarah Cannon Research UK, London (S.C.), and the Royal Cornwall Hospital, Truro (A. Thomson) - all in the United Kingdom; Auckland City Hospital, Auckland (N.J.L.), and the Waikato District Health Board, Hamilton (A. Tan) - both in New Zealand; Cancer Trials Ireland (J.M., R.M.), Mater Misericordiae University Hospital (J.M.), and St. Vincent's University Hospital and University College Dublin (R.M.D.) - all in Dublin; and Dana-Farber Cancer Institute and Harvard Medical School (C.J.S.) - both in Boston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1903835DOI Listing
July 2019

Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series.

Health Sci Rep 2019 Mar 1;2(3):e115. Epub 2019 Feb 1.

Department of Cancer Medicine, Melbourne Peter MacCallum Cancer Centre Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hsr2.115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427059PMC
March 2019

Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.

Neoplasia 2019 04 20;21(4):389-400. Epub 2019 Mar 20.

Cancer Program, Biomedicine Discovery Institute, Monash University, Victoria, Australia; Department of Biochemistry and Molecular Biology, Monash University, Victoria, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2019.02.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426874PMC
April 2019

Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel.

J Mol Diagn 2019 05 5;21(3):418-426. Epub 2019 Feb 5.

Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15251578183023
Publisher Site
http://dx.doi.org/10.1016/j.jmoldx.2018.12.001DOI Listing
May 2019

Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics.

Eur Urol 2019 06 5;75(6):927-928. Epub 2019 Jan 5.

The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.12.039DOI Listing
June 2019

[Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer - Author's reply.

Lancet Oncol 2018 08;19(8):e373

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30534-5DOI Listing
August 2018

Mortality due to immunotherapy related hepatitis.

J Hepatol 2018 10 6;69(4):976-978. Epub 2018 Aug 6.

Department of Gastroenterology & Hepatology, Royal Melbourne Hospital, Melbourne, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01688278183216
Publisher Site
http://dx.doi.org/10.1016/j.jhep.2018.06.012DOI Listing
October 2018

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Eur Urol 2018 11 23;74(5):562-572. Epub 2018 Jul 23.

Monash Partners Comprehensive Cancer Consortium, Monash Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Melbourne Urological Research Alliance (MURAL), Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.06.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351078PMC
November 2018

[Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.

Lancet Oncol 2018 06 8;19(6):825-833. Epub 2018 May 8.

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30198-0DOI Listing
June 2018

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

N Engl J Med 2018 May 15;378(19):1789-1801. Epub 2018 Apr 15.

From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille (J.-J.G.) - all in France; Netherlands Cancer Institute-Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical Center Nijmegen, Nijmegen (R.K.) - all in the Netherlands; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo (M. Mandala), Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione G. Pascale, Naples (P.A.A.), and Universita Degli Studi Di Siena-Policlinico le Scotte, Siena (M. Maio) - all in Italy; Melanoma Institute Australia, the University of Sydney, and Mater and Royal North Shore Hospitals (G.V.L.) and Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney (M.S.C.), Sydney, Princess Alexandra Hospital, University of Queensland, Brisbane (V.A.), Alfred Hospital (A.H.) and Peter MacCallum Cancer Centre (S. Sandhu), Melbourne, VIC, and Fiona Stanley Hospital-University of Western Australia-Edith Cowan University Perth, Perth (A.K.) - all in Australia; Cancer Research Center, Moscow (M.L.); Royal Marsden Hospital, London (J.L.); Hospital Clinic Universitari de Barcelona, Barcelona (S.P.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); University Hospital Essen, Essen and German Cancer Consortium, Heidelberg (D.S.), and the Skin Cancer Center, Department of Dermatology, Hannover Medical School, Hannover (R.G.) - all in Germany; Washington University School of Medicine, St. Louis (L.H.-A.); Centre Hospitalier de l'Université de Montréal (CHUM), Centre de Recherche du CHUM, Montreal (R.J.); Christie NHS Foundation Trust, Manchester, United Kingdom (P.L.); Merck, Kenilworth, NJ (N.I.); and the European Organization for the Research and Treatment of Cancer Headquarters, Brussels (S.M., S. Suciu).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1802357DOI Listing
May 2018

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Lancet Oncol 2018 05 27;19(5):672-681. Epub 2018 Mar 27.

Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia; Medical, Dental and Health Sciences, University of Melbourne, Parkville, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30139-6DOI Listing
May 2018

Reply to M. Horiguchi et al.

J Clin Oncol 2018 03 16;36(7):722-723. Epub 2018 Jan 16.

Serigne N. Lo, Melanoma Institute Australia and the University of Sydney, Sydney, New South Wales, Australia; and Shahneen Sandhu, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.5347DOI Listing
March 2018

Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma.

J Clin Oncol 2017 12 19;35(34):3792-3793. Epub 2017 Oct 19.

Matteo S. Carlino, Westmead and Blacktown Hospitals and University of Sydney, Sydney, New South Wales, Australia; and Shahneen Sandhu, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.2055DOI Listing
December 2017

When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the 'Australian guidelines for the management of cutaneous melanoma'.

Australas J Dermatol 2017 Nov 17;58(4):274-277. Epub 2017 Jul 17.

Melanoma Institute Australia, Poche Centre, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.12662DOI Listing
November 2017

Relevance of DNA damage repair in the management of prostate cancer.

Curr Probl Cancer 2017 Jul - Aug;41(4):287-301. Epub 2017 Jun 27.

Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.currproblcancer.2017.06.001DOI Listing
June 2017

The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer.

Eur Urol 2017 05 26;71(5):748-749. Epub 2017 Jan 26.

Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.01.025DOI Listing
May 2017

Practical Polling for Prostate Cancer: AR-V7-based Treatment Selection.

Eur Urol 2017 06 11;71(6):883-885. Epub 2017 Jan 11.

Department of Genitourinary Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.12.028DOI Listing
June 2017

The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.

Clin Cancer Res 2016 Nov 2;22(22):5539-5552. Epub 2016 Aug 2.

Cancer Program, Biomedicine Discovery Institute and Department of Anatomy & Developmental Biology, Monash University, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0124DOI Listing
November 2016

Recent Insights and Advances in the Management of Merkel Cell Carcinoma.

J Oncol Pract 2016 07;12(7):637-46

Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2016.013367DOI Listing
July 2016

Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.

Eur J Cancer 2016 07 7;61:111-21. Epub 2016 May 7.

Molecular Therapy and Pharmacogenomic Unit, ASST di Cremona, Viale Concordia 1, 26100, Cremona, Italy; Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.04.002DOI Listing
July 2016

Integration of Immuno-Oncology and Palliative Care.

J Clin Oncol 2016 05 29;34(13):1561-2. Epub 2016 Feb 29.

Peter MacCallum Cancer Centre, East Melbourne; and University of Melbourne, Parkville, Victoria, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.4146DOI Listing
May 2016

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

N Engl J Med 2015 Oct;373(18):1697-708

From the Institute of Cancer Research (J.M., S.C., S.S., S.M., H.M., R.P.-L., D.N.R., A.O., N.T., G.B., N.P., P.F., A.G., I.F., C.P., G.S., D.B., J.G., Z.Z., C.T.W., R.F., R.R., B.E., G.F., D. Roda, W.Y., R.B., H.P., R.A., A.S., R.E., G.A., C.J.L., A.A., E.H., J.S.B.), the Royal Marsden NHS Foundation Trust (J.M., S.S., R.P.-L., A.O., N.T., D.B., Z.Z., R.F., D. Roda, R.E., G.A., J.S.B.), and University College London Hospital (U.M.), London, Queen's University, Belfast (S.J.), University of Leeds, Leeds (C.R.), Churchill Hospital, Oxford (A.P.), University of Liverpool, Liverpool (S.H.), Beatson West of Scotland Cancer Centre, Glasgow (R.J.), and Christie Hospital, Manchester (T.E.) - all in the United Kingdom; the University of Michigan, Ann Arbor (D. Robinson, Y.-M.W., X.C., L.P.K., F.Y.F., A.M.C.); Weill Cornell Medical College, New York (M.A.R.); and Thomas Jefferson University, Philadelphia (K.E.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1506859DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228595PMC
October 2015

Use of vemurafenib in a patient unable to swallow whole.

J Oncol Pharm Pract 2016 Oct 27;22(5):733-7. Epub 2015 Aug 27.

Department of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155215603231DOI Listing
October 2016

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

J Clin Oncol 2015 Apr 23;33(12):1348-55. Epub 2015 Mar 23.

Howard I. Scher, Glenn Heller, Daniel C. Danila, and Martin Fleisher, Memorial Sloan Kettering Cancer Center; Howard I. Scher and Daniel C. Danila, Weill Cornell Medical College; Xiaoyu Jia, Columbia University, New York, NY; Arturo Molina, Janssen Research & Development, Menlo Park; Weimin Peng, Janssen Research & Development, Los Angeles; Thian Kheoh, Janssen Research & Development, San Diego, CA; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, Ruth Riisnaes, and Johann S. de Bono, Institute of Cancer Research; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, and Johann S. de Bono, Royal Marsden Hospital, Sutton, United Kingdom; Robert McCormack, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski and Marc Buyse, International Drug Development Institute, Louvain-la-Neuve, Belgium.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/03/23/JCO.2014.55
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.55.3487
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.55.3487DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397279PMC
April 2015

Cell cycle control as a promising target in melanoma.

Curr Opin Oncol 2015 Mar;27(2):141-50

aDepartment of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne bDepartment of Pathology, University of Melbourne, Parkville cDepartment of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy dMolecular Oncology Laboratory, Oncogenic Signalling and Growth Control Program eTranslational Research Laboratory, Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000159DOI Listing
March 2015

Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

Nat Rev Urol 2015 Jan;12(1):37-47

Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2014.345DOI Listing
January 2015

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.

Melanoma Res 2014 Oct;24(5):504-8

aDepartment of Medical Oncology, Cancer Centre, Sir Charles Gairdner Hospital bSchool of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia cPeter MacCallum Cancer Centre, East Melbourne dSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria eMelanoma Institute Australia, North Sydney fUniversity of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000099DOI Listing
October 2014

Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.

Clin Cancer Res 2014 04 17;20(7):1925-34. Epub 2014 Feb 17.

Authors' Affiliations: Royal Marsden NHS Foundation Trust and The Institute of Cancer Research UK, Sutton; Institut Català d'Oncologia, L'Hospitalet, Barcelona; University of Surrey, Surrey, United Kingdom; Yale University Cancer Center, New Haven; Centre Hospitalier de l'Universite de Montreal, Montreal; A Coruña University Hospital, A Coruña, Spain; Kantonsspital St. Gallen, St. Gallen, Switzerland; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Pfizer Inc, Groton, Connecticut; and Lady Davis Institute for Medical Research, Jewish General Hospital and McGill University, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1869DOI Listing
April 2014

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.

Clin Cancer Res 2013 Oct 6;19(19):5485-93. Epub 2013 Aug 6.

Authors' Affiliations: The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton; Edinburgh Cancer Research UK Center, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh; The Cancer Research UK Gene Function Laboratory; Breakthrough Breast Cancer Research Center; Tumour Profiling Unit, The Institute of Cancer Research, London, United Kingdom; University of California San Francisco, San Francisco, California; Department of Medical Oncology, Prince of Wales Clinical School, Prince of Wales Hospital, Sydney, Australia; The Chaim Sheba Medical Center, Tel Hashomer, Israel; Princess Margaret Hospital, Toronto, Canada; Oncologisch Centrum Vrije Universiteit Brussel, Brussels, Belgium; and Dana Farber Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1262DOI Listing
October 2013

Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.

Eur Urol 2013 Aug 4;64(2):300-6. Epub 2013 Jan 4.

Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838120155
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2012.12.029DOI Listing
August 2013

PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer.

Drugs 2012 Aug;72(12):1579-90

Drug Development Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/11635510-000000000-00000DOI Listing
August 2012

HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.

Curr Drug Targets 2011 Dec;12(14):2045-58

Royal Marsden NHS Foundation Trust and The Institute of Cancer Research Downs Road, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138945011798829348DOI Listing
December 2011

The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.

Curr Drug Targets 2011 Dec;12(14):2034-44

The Royal Marsden NHS Foundation Trust, Downs Road Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138945011798829438DOI Listing
December 2011

Beyond hormone therapy for prostate cancer with PARP inhibitors.

Cancer Cell 2011 May;19(5):573-4

Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5PT, UK.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108110015
Publisher Site
http://dx.doi.org/10.1016/j.ccr.2011.05.003DOI Listing
May 2011

Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials.

Clin Cancer Res 2011 Aug 29;17(15):5188-96. Epub 2011 Apr 29.

Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-3019DOI Listing
August 2011

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.

Nat Rev Clin Oncol 2011 May 5;8(5):302-6. Epub 2011 Apr 5.

Drug Development Unit, Royal Marsden Hospital, Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2011.42DOI Listing
May 2011

Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.

CA Cancer J Clin 2011 Jan-Feb;61(1):31-49. Epub 2011 Jan 4.

Drug Development Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.20095DOI Listing
March 2011

Horizon scanning for novel therapeutics for the treatment of prostate cancer.

Expert Opin Investig Drugs 2010 Dec 24;19(12):1487-502. Epub 2010 Sep 24.

The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Section of Medicine, Drug Development Unit, Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2010.514261DOI Listing
December 2010

Envisioning the future of early anticancer drug development.

Nat Rev Cancer 2010 07 10;10(7):514-23. Epub 2010 Jun 10.

Drug Development Unit, Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrc2870
Publisher Site
http://dx.doi.org/10.1038/nrc2870DOI Listing
July 2010

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.

Eur J Cancer 2010 Jan;46(1):9-20

The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S095980490900779
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2009.10.021DOI Listing
January 2010